4P7E

Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 0.267 
  • R-Value Work: 0.205 
  • R-Value Observed: 0.208 

wwPDB Validation   3D Report Full Report



Literature

Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634.

Menet, C.J.Fletcher, S.R.Van Lommen, G.Geney, R.Blanc, J.Smits, K.Jouannigot, N.Deprez, P.van der Aar, E.M.Clement-Lacroix, P.Lepescheux, L.Galien, R.Vayssiere, B.Nelles, L.Christophe, T.Brys, R.Uhring, M.Ciesielski, F.Van Rompaey, L.

(2014) J Med Chem 57: 9323-9342

  • DOI: 10.1021/jm501262q
  • Primary Citation of Related Structures:  
    4P7E

  • PubMed Abstract: 
  • Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function. Blockade of the JAK-STAT pathway with a small molecule has been shown to provide therapeutic immunomodulation. Having ident ...

    Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function. Blockade of the JAK-STAT pathway with a small molecule has been shown to provide therapeutic immunomodulation. Having identified JAK1 as a possible new target for arthritis at Galapagos, the compound library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by 3. Optimization within this chemical series led to identification of GLPG0634 (65, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn's disease (CD).


    Organizational Affiliation

    Galapagos NV , Generaal de Wittelaan L11A3, 2800 Mechelen, Belgium.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Tyrosine-protein kinase JAK2AB293Homo sapiensMutation(s): 1 
Gene Names: JAK2
EC: 2.7.10.2
Find proteins for O60674 (Homo sapiens)
Explore O60674 
Go to UniProtKB:  O60674
NIH Common Fund Data Resources
PHAROS  O60674
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
2HB
Query on 2HB

Download Ideal Coordinates CCD File 
A, B
N-(5-{4-[(1,1-dioxidothiomorpholin-4-yl)methyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
C21 H23 N5 O3 S
RIJLVEAXPNLDTC-UHFFFAOYSA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
PTR
Query on PTR
A,BL-PEPTIDE LINKINGC9 H12 N O6 PTYR
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
2HBIC50:  25   nM  BindingDB
2HBIC50:  10000   nM  BindingDB
2HBIC50:  31.3700008392334   nM  BindingDB
2HBIC50:  41.15999984741211   nM  BindingDB
2HBIC50:  100   nM  BindingDB
2HBIC50:  460   nM  BindingDB
2HBIC50:  3524   nM  BindingDB
2HBIC50:  4546   nM  BindingDB
2HBIC50:  17453   nM  BindingDB
2HBIC50:  167.33999633789062   nM  BindingDB
2HBIC50:  55.4900016784668   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 0.267 
  • R-Value Work: 0.205 
  • R-Value Observed: 0.208 
  • Space Group: P 41
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 111.39α = 90
b = 111.39β = 90
c = 71.08γ = 90
Software Package:
Software NamePurpose
iMOSFLMdata reduction
SCALAdata scaling
PDB_EXTRACTdata extraction
PHASERphasing
REFMACrefinement
MOSFLMdata reduction

Structure Validation

View Full Validation Report



Entry History 

Revision History 

  • Version 1.0: 2014-11-19
    Type: Initial release
  • Version 1.1: 2014-12-10
    Changes: Database references
  • Version 2.0: 2019-08-21
    Changes: Atomic model, Data collection, Derived calculations